Epstein Secrets

ve and quantitative information about investment processes ■ Regular meetings with investors ■ Investments by partners and employees comprise 7% of Och-Ziff's AUMI ■ Och-Ziff's partners receive a substantial majority of their compensation from distributions tied to profitability As of September I. 2015 u

Och-Ziff in 2009, Mr. Clavel was a Senior Anal at Silverpoint Capital. Before that, he worked as a Vice President at GSC Group and as an Analyst at Schroder Salomon Smith Barney. Mr. Clavel holds an M. in Accounting and Finance from the London School of Economics and Political Science. Tajinder Sidhu is a Managing Director

Mount Sinai Medical Center. Harold Kelly is Head of Global Convertible and Derivative Arbitrage and Risk Management for Och-Ziff and is a member of Och-Ziff's Partner Management Committee. Mr. Kelly is also an Executive Managing Director. Prior to joining Och-Ziff in 1995, Mr. Kelly spent seven years tradi

h-Ziff in 2009, Mr. Clavel was a Senior Analyst at Silverpoint Capital. Before that, he worked as a Vice President at GSC Group and as an Analyst at Schroder Salomon Smith Barney. Mr. Clavel holds an M.S. in Accounting and Finance from the London School of Economics and Political Science. Tajinder Sidhu is a Managing Directo

Mount Sinai Medical Center. Harold Kelly is Head of Global Convertible and Derivative Arbitrage and Risk Management for Och-Ziff and is a member of Och-Ziff's Partner Management Committee. Mr. Kelly is also an Executive Managing Director. Prior to joining Och-Ziff in 1995, Mr. Kelly spent seven years tradi

h-Ziff in 2009, Mr. Clavel was a Senior Analyst at Silverpoint Capital. Before that, he worked as a Vice President at GSC Group and as an Analyst at Schroder Salomon Smith Barney. Mr. Clavel holds an M.S. in Accounting and Finance from the London School of Economics and Political Science. Tajinder Sidhu is a Managing Directo